FDA Registered  
For healthcare providers

For patients with heart
    diseases
and those at risk

For medical device industry

For pharmaceutical industry

For those who want to maintain
    a healthy life-style


Gold-standard, professional-quality
    ECG system for everyone


Long-term monitoring

Remote analysis
National Institutes of Health give
    Pelex a high priority score


A clinical trial successfully completed
    at  UPMC


What do leading cardiologists have
    to say?


A new US patent granted
National Institutes of Health expert panel gives a high priority score to Pelex-04...
  Pelex-04 selected by World Best Technologies 2005

What leading cardiologists say about Pelex-04


December 27, 2007.
United States Patents and Trademark Office issues a Notice of Allowance for a new US Patent covering network-distributed, multi-scale technology.
This patent further extends and solidifies PinMed's intellectual property portfolio as a leader in Network-distributed, Personalized, Intelligent, Medical technologies. To learn more about PinMed's intellectual property, please follow this link.


December 15, 2007.
European Patent Office issues a Notice of Allowance for Pelex technology.


August 25, 2006.
PinMed is selected to participate in the NIH Commercialization Assistance Program.
The program is designed to help some of the nation's most promising life-science small companies develop their commercial businesses and transition their SBIR-developed products into the marketplace.


August 10, 2006.
PinMed and PLSG Press Release discusses FDA clearance.   learn more


July 24, 2006.
PinMed receives FDA clearance for Pelex-04 suite of products.


May 15, 2006. PinMed receives Phase II NIH Award with a high priority score.
The second NIH Award raises the total amount of NIH funding to PinMed over the past 2 years to over $900,000.


September 1, 2005.
United States Patents and Trademark Office issues a new patent for Pelex technology.


July 26, 2005.
National Institutes of Health expert review committee gives Pelex-04 a high priority score.
A  panel of the leading experts of the National Institutes of Health Review Committee gives Pelex-04 a high priority score of 153. In 2003, the National Institutes of Health review committee also gave a high score and funding for the initial development of Pelex technology.


April 15. 2005.
What leading cardiologists say about Pelex-04.
A group of leading experts in cardiology enthusiastically received Pelex technology. Some of their remarks are listed below:

"As a practicing electrophysiologist, I can envision multiple clinical uses for the PELEX system once it is approved by the FDA... I think this technology will be extremely useful, both for my own research applications, and also likely for clinical practice."

 Rachel Lampert, MD, Associate Professor of Medicine (Section of Cardiology/Electrophysiology), Yale University School of Medicine
 

"There is a need for such a system; I am not aware of any other system like this one. This system takes ECG analysis into another dimension. Instead of "linear" approaches, which use small lengths (3-10 sec) of ECG, this method allows serial comparisons of long segments of data, which provide robust characterization of data. This approach provides much more information than the traditional, short-term 12-lead ECG (which is 50-years old); it provides a tool to study dynamics of heart rate variability, restitution, etc. I would be very interested in using this system in my research. In particular, I would be very interested in analyzing dynamics of repolarization along with the cycle length. Some potential applications are:

-          ECG fingerprinting,

-          Normal patterns

-          Patterns altered by disease

-          Patterns altered by drugs

-          Monitoring changes in the course of the disease

-          Monitoring changes due to pharmacological agents

-          Autonomic nervous system effects."

Robert L. Lux, PhD, Professor of Medicine, Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, Utah, Board Member of the International Society for Computerized Electrocardiology.

"PELEX can save a lot of emergency visits for cardiac and syncope patients. PELEX can replace Holter Monitoring, event monitoring, and loop recorders."

Samir Saba, MD, Director of Cardiac Electrophysiology Program, Cardiovascular Institute, University of Pittsburgh Medical Center

"PELEX is a great clinical tool for management of atrial fibrillation, palpitation syndrome, long QT-syndrome, QT-evaluation in patients with antiarrhythmic drugs. Pelex is also a great research tool.  There is a need for such a system like PELEX, and I never saw a system like this one."

 Raul Weiss, MD, FACC, Partner and Clinical Cardiac Electrophysiologist at the MidOhio Cardiology and Vascular Consultants, Inc. (one of the leading and largest cardiology practices), Columbus, Ohio, Board-certified in internal medicine, cardiology, and electrophysiology, Member, Heart Rhythm Society, American Heart Association, Fellow, American College of Cardiology

"PELEX takes diagnostic electrophysiology to a new level, particularly, with unstable arrhythmic substrates, such as genetic repolarization disorders and more common syndromes, such as paroxysmal atrial fibrillation and ventricular tachycardias. It has the capability to be widely used for ambulatory arrhythmia monitoring and can potentially substitute invasive implantable loop recorders.

Raveen Bazaz, MD, Assistant Professor of Medicine, Clinical Cardiac Electrophysiologist, Cardiovascular Institute, University of Pittsburgh Medical Center


March 10, 2005. Pelex-04 has been selected by the World Best Technologies 2005 Tradeshow.
The World Best Technologies tradeshow selects 25-75 best technologies nationwide with the highest market and technology potential.

 

Copyright 2005 © PinMed, Inc. All rights reserved.